证券日报网讯9月4日晚间，天宇股份（300702）发布公告称，公司将于2025年9月8日召开2025年第二次 临时股东大会。本次股东大会将审议《关于日常关联交易预计的议案》等。 ...

Group 1 - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Norde Pharmaceutical Co., Ltd., has recently received the Drug Registration Certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [2]

Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]

Group 1 - The core point of the article is that Tianyu Co., Ltd. has received approval from the National Medical Products Administration for the drug registration certificate of Candesartan Cilexetil Tablets, which are indicated for primary hypertension [1] Group 2 - The approval was granted to Zhejiang Norde Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tianyu Co., Ltd. [1] - Candesartan Cilexetil Tablets are specifically used for the treatment of primary hypertension [1]

格隆汇9月4日丨天宇股份(300702.SZ)公布，公司全资子公司浙江诺得药业有限公司(简称"诺得药业")于 近日收到国家药品监督管理局核准签发的关于坎地沙坦酯片的《药品注册证书》。 坎地沙坦酯片适用于原发性高血压。根据国家药监局网站数据查询，截至公告日，该制剂除诺得药业 外，国内生产商另有天地恒一制药股份有限公司、广州白云山天心制药股份有限公司等11家企业。 ...

Group 1 - The company Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [1] - Candesartan Cilexetil Tablets are indicated for primary hypertension, with a total R&D investment of approximately 11.4476 million yuan by Node Pharmaceutical and its subsidiaries [1] - The projected sales revenue for Candesartan Cilexetil Tablets in domestic sample hospitals and urban retail pharmacies is approximately 294 million yuan in 2024 [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration, indicating the product's approval for the treatment of primary hypertension [1]. Company Summary - Tianyu Co., Ltd. has successfully obtained regulatory approval for Candesartan Cilexetil Tablets, which are indicated for primary hypertension [1]. - The approval enhances the product portfolio of Zhejiang Node Pharmaceutical Co., Ltd., potentially increasing its market presence in the hypertension treatment segment [1].

Group 1 - The company Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary Zhejiang Norde Pharmaceutical Co., Ltd. has recently received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [1] - Candesartan Cilexetil Tablets are indicated for the treatment of primary hypertension [1]

| 药品名称 | 坎地沙坦酯片 | | | | --- | --- | --- | --- | | 英文名 | Candesartan | Cilexetil | Tablets | | 剂型 | 片剂 | | | | 规格 | 4mg | | | | 是否处方药 | 是 | | | | 申请事项 | 药品注册（境内生产） | | | | 注册分类 | 化学药品 | | | | 药品批准文号 | 国药准字 | H20258176 | | | 药品批准文号有效期 | 至 2028 年 09 | 月 04 | 日 | 1、药品基本情况 证券代码：300702 证券简称：天宇股份 公告编号：2025-061 2、药物的其他情况 浙江天宇药业股份有限公司 关于全资子公司药品获得批准的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）全资子公司浙江诺得药业 有限公司（以下简称"诺得药业"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的关于坎地沙坦酯片的《药品注册证书》 ...

证券代码：300702 证券简称：天宇股份 公告编号：2025-060 浙江天宇药业股份有限公司 关于召开 2025 年第二次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）于 2025 年 8 月 23 日在巨 潮资讯网（http://www.cninfo.com.cn）上发布了《关于召开 2025 年第二次临时股 东大会的通知》（公告编号：2025-057）。现将本次会议的有关事项再次提示如 下： 一、召开会议的基本情况 1、股东大会届次：2025 年第二次临时股东大会。 2、股东大会的召集人：公司董事会。 公司于 2025 年 8 月 22 日召开的第五届董事会第十四次会议，审议通过了《关 于召开 2025 年第二次临时股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行政 法规、部门规章、规范性文件和公司章程的规定。 7、会议出席对象： 1 / 7 （1）截至 2025 年 9 月 3 日下午深圳证券交易所收市时，在 ...